Loading...
•
Dec 31, 2019
Gossamer Bio Q4 2019 Earnings Report
Gossamer Bio reported financial results for Q4 2019 and provided a business update.
Key Takeaways
Gossamer Bio reported cash, cash equivalents and marketable securities of $401.8 million as of December 31, 2019. R&D expenses for the quarter ended December 31, 2019 were $42.6 million, and the net loss for the three months ended December 31, 2019, was $54.7 million, or $0.89 per share.
Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020
Cash, cash equivalents and marketable securities totaled $401.8 million at year-end 2019
R&D expenses were $42.6 million for the quarter ended December 31, 2019
Net loss for the three months ended December 31, 2019, was $54.7 million, or $0.89 per share